HYBRID NANOCOMPOSITE COMPOSED OF PLANT EXOSOMES AND FUSIONED NIOSOMES HAVING MULTIPLE BIOACTIVE SUBSTANCES
A hybrid nanocomposite of vegan exosomes and niosomes, prepared via ultrasonic fusion, addresses vegan certification and delivery stability issues, enabling effective delivery of multiple bioactive substances with enhanced skin penetration.
Patent Information
- Application Number
- FR2026006275
- Authority / Receiving Office
- FR · FR
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2026-05-12
- Publication Date
- 2026-11-13
AI Technical Summary
Conventional bioactive substance delivery technologies face challenges with animal-derived exosomes, such as vegan certification issues, ethical concerns, immune reactions, and limitations in delivering multiple substances effectively and stably, while niosomes offer stability and skin permeability but lack simultaneous delivery solutions with exosomes.
A hybrid nanocomposite is formed by fusing vegan exosomes and niosomes through ultrasonic treatment, incorporating multiple bioactive substances like nucleic acids, phytochemicals, and peptides, enhancing stability and skin penetration.
The hybrid nanocomposite provides a stable and ethical delivery system for multiple bioactive substances, ensuring improved skin and tissue penetration and bioavailability, addressing limitations of single-carrier systems.
Abstract
Description
Title of the invention: HYBRID NANOCOMPOSITE COMPOSED OF PLANT EXOSOMES AND FUSIONED NIOSOMES HAVING MULTIPLE BIOACTIVE SUBSTANCES
[0001] CROSS-REFERENCE TO A RELATED PATENT APPLICATION
[0002] The present application claims the benefit of Korean patent application No. 10-2025-0061001, filed on May 12, 2025 with the Korean Intellectual Property Office, the disclosure of which is incorporated herein in its entirety by way of reference. technical field
[0003] This disclosure relates to a method for preparing a hybrid nanocomposite in which exosomes and niosomes are fused, capable of stably and efficiently delivering various bioactive substances to the skin or tissues of a subject using exosomes and niosomes, which are biocompatible and highly efficient delivery systems, and also relates to the uses of the hybrid nanocomposite prepared by said method.
[0004] CONTEXT
[0005] Conventional bioactive substance delivery technologies primarily employ a method of delivering active ingredients using liposomes, niosomes, nanoparticles, or exosomes as a single carrier. Among these, exosomes are extracellular vesicles composed of a phospholipid bilayer with a size of 50 to 200 nm and are actively studied in the cosmetic and biomedical fields based on advantages such as intercellular signal transmission, biocompatibility, and permeability.
[0006] However, most conventional exosome-based technologies use exosomes extracted from animal or human stem cells, and these raw materials have limitations such as difficulties in obtaining vegan certification, ethical issues, immune reactions, and the possibility of pathogenic contamination.
[0007] Accordingly, Korean patent No. 10-2450893 describes a technology that uses exosomes derived from hydrangea leaves, and, in addition to the technology, Korean patent publication No. 10-2025-0027604 describes hybrid exosomes obtained by fusion of hydrangea-derived exosomes with synthetic liposomes.
[0008] However, these conventional technologies simply use plant-derived exosomes or rely on a simple process of mixing or physically incubating exosomes and a single ingredient (e.g., sapogenin, etc.), and thus present limitations in terms of eliciting complex bioactive effects. In particular, there is a lack of structural fusion technology capable of stably incorporating two or more bioactive substances within a single system and, at the same time, improving skin and tissue penetration and bioavailability.
[0009] Meanwhile, recently, niosomes have presented a bilayer structure similar to that of liposomes, but with excellent stability and cost-effectiveness based on a non-ionic surfactant, as well as better skin permeability, and are thus attracting attention as an alternative system.
[0010] However, technologies which allow the stable delivery of various bioactive substances using both niosomes and exosomes simultaneously have not yet been sufficiently developed.
[0011] Accordingly, the present inventors have developed a technology for structurally incorporating multiple bioactive substances such as nucleic acids, phytochemicals and peptides, and for stably delivering them to a subject using niosomes and exosomes, so as to carry out the present disclosure.
[0012] [Prior art literature]
[0013] [Patent document]
[0014] (Patent Document 0001) Korean Patent Publication No. 10-2019-0038743 (published on April 9, 2019)
[0015] (Patent Document 0002) Korean Patent Publication No. 10-2024-0011894 (published on January 29, 2024)
[0016] (Patent Document 0003) Korean Patent Publication No. 10-2025-0027604 (published on February 27, 2025)
[0017] (Patent Document 0004) Korean Patent No. 10-2450893 (published on October 6, 2022)
[0018] SUMMARY
[0019] TECHNICAL PROBLEM
[0020] One objective of this disclosure is to propose a safe and ethical nanocomposite based on vegan raw materials. Conventional exosomes are primarily derived from animal or human stem cells, which presents challenges in obtaining vegan certification and raises concerns regarding ethical issues and immune responses. In contrast, one objective of this disclosure is to propose a safer and more ethical nanocomposite using exosomes derived from plants, plant callus, or microorganisms (vegan exosomes), rather than animals.
[0021] Another objective of this disclosure is to propose a nanocomposite that provides complex physiological effects. Since conventional technologies are used by simply incubating or mixing a single bioactive substance with exosomes, there is a limitation in terms of inducing complex physiological effects (such as anti-inflammatory, antioxidant, regenerative, etc.). In contrast, one objective of this disclosure is to propose a nanocomposite that provides multiple effects by simultaneously incorporating multiple bioactive substances such as nucleic acids, phytochemicals, and peptides.
[0022] Another objective of this disclosure is to propose a nanocomposite that overcomes the instability and permeability limitations associated with the use of exosomes alone. The exosome itself exhibits excellent biocompatibility, but physical instability, formulation difficulties, and permeability limitations. In contrast, this disclosure aims to propose a nanocomposite with a dual protective structure and improved penetration into skin or tissues through incorporation with niosomes.
[0023] Another object of this disclosure is to propose a method for preparing the nanocomposite having the utility described above.
[0024] Another object of this disclosure is to propose a composition comprising the nanocomposite having the utility described above.
[0025] Another object of this disclosure is to propose a method for ensuring physiological activity elicited by the multiple bioactive substances inserted in the nanocomposite by administering the nanocomposite having the utility described above to a subject.
[0026] TECHNICAL SOLUTION
[0027] According to one aspect, the present disclosure proposes a method for preparing a hybrid nanocomposite in which vegan exosomes and niosomes are fused.
[0028] According to one specific aspect, the process, according to this disclosure, for preparing the hybrid nanocomposite in which vegan exosomes and niosomes are fused comprises:
[0029] (S 10) the preparation of vegan exosomes;
[0030] (S20) the insertion of multiple bioactive substances into vegan exosomes of stage (S 10);
[0031] (S30) the preparation of niosomes; and
[0032] (S40) the fusion of vegan exosomes in which the multiple substances bioactives of stage (S20) are inserted and niosomes of stage (S30) by subjecting them to ultrasonic treatment.
[0033] Below, with reference to [Fig.2], the process of preparing, according to this disclosure, the hybrid nanocomposite in which vegan exosomes and niosomes are fused will be described in detail.
[0034] Step (S 10) is a step in the preparation of vegan exosomes.
[0035] In this disclosure, the exosome is an extracellular vesicle derived from plants or microorganisms, rather than an extracellular vesicle derived from animals, and plant-derived cells include undifferentiated cells, stem cells, calluses, etc. Since the exosome is an extracellular vesicle not derived from animal cells, it may be referred to as a vegan exosome in this description.
[0036] The term "plant" refers to both woody and herbaceous plants. Examples of the latter include fruit trees such as apple, pear, persimmon, grapevines and ginkgo trees; conifers such as pines, Korean pines and larches; deciduous trees such as camellias, forsythias, magnolias and cherry trees; annual herbaceous plants such as cosmos, purslane and soybeans; biennial herbaceous plants such as barley, wheat, shepherd's purse and Arabidopsis; and perennial herbaceous plants such as dandelion, bellflower and mugwort.
[0037] The microorganism includes all microorganisms having cells, such as eukaryotes or prokaryotes such as bacteria, fungi and yeasts.
[0038] The undifferentiated cell is a cell before differentiation and can also be referred to as a “stem cell” and / or “callus”.
[0039] A stem cell is a cell capable of differentiating into all cell types or into cells of a specific tissue in a plant, and examples of this include the apical meristem, the cambium, stomatal lineage stem cells, etc., but not necessarily limited to them.
[0040] A callus can be a mass of undifferentiated, amorphous parenchyma cells from a plant, and can be a callus isolated from plant tissues, a callus obtained by inducing a dedifferentiation process in a plant excipient, or a callus propagated by callus culture. The plant tissue can be a specific part or all parts of a plant, such as a flower, leaf, stem, branch, fruit, root, etc.
[0041] In a specific embodiment, the exosome may be an exosome derived from a microorganism of the genus Lactobacillus, from a camellia leaf, from a camellia callus, etc.
[0042] In this disclosure, the term "exosome preparation" refers to the isolation of exosomes from plant-derived cells or microorganisms, excluding animal cells, and may include a concentration intended to increase the concentration of isolated exosomes after isolation.
[0043] The isolation of exosomes from plant-derived or microorganism-derived cells is not necessarily limited to this, but can be carried out by processes such as centrifugation, ultrasonic centrifugation, ultrafiltration, chromatography, etc. after homogenization of the cells (or of the cell culture solution).
[0044] Cell homogenization is a process designed to isolate exosomes present in cells in addition to exosomes secreted by the cells. Exosomes can be isolated by mechanical homogenization and rupture of the cell wall and / or cell membrane. Mechanical homogenization, rupture, and isolation can be carried out, for example, by a homogenizer, a high-pressure homogenizer, an extracorporeal shock wave, an ultrasonicator, etc. Rupture and isolation can be performed using a single device or multiple devices.
[0045] The concentration of isolated exosomes refers to the purification of isolated exosomes in order to increase their concentration, and can be carried out by a process which consists of performing cell homogenization two or more times, or by a tangential flow filtration (TFF) process, etc.
[0046] As a specific example, the isolation and concentration of exosomes can be carried out by primary homogenization of plant-derived or microorganism-derived cells with the high-pressure homogenizer in order to isolate the exosomes, and then by secondary homogenization of these using the ultrasonicator.
[0047] As another specific example, the isolation and concentration of exosomes can be carried out by primary homogenization of plant- or microorganism-derived cells with the high-pressure homogenizer in order to isolate the exosomes, and then subjecting them to tangential flow filtration.
[0048] Step (S20) is a step which consists of inserting the multiple bioactive substances into the vegan exosomes prepared in step (S10).
[0049] In this disclosure, multiple bioactive substances refers to two or more bioactive substances to be inserted into exosomes. Bioactive substances are substances present in living organisms such as plants, animals, microorganisms, etc., and which affect various physiological activities. Furthermore, bioactive substances may be substances chemically synthesized or produced by recombinant microorganisms so as to have chemical structures or constituent components identical to those of substances present in a living organism at 80% or more, preferably 90% or more, while affecting physiological activity at levels equivalent to those of substances present in the living organism.
[0050] In this disclosure, insertion refers to the fact that the bioactive substances are positioned inside the vegan exosomes or are attached to the surface of the exosomes or between the membranes of the exosomes by a chemically covalent or non-covalent bond.
[0051] According to one embodiment of this disclosure, the bioactive substances are not necessarily limited to these, but may be one or more substances selected from the group consisting of proteins, peptides, extracellular matrices, nucleic acids, lipids, carbohydrates, drugs and phytochemicals.
[0052] For example, the protein may comprise one or more proteins selected from the group consisting of plasma proteins, hormones, cytokines, enzymes, antibodies, growth factors, transcriptional regulatory factors, blood clotting factors, vaccines, differentiation clusters and receptor antagonists.
[0053] For example, the plasma protein may comprise one or more proteins selected from the group consisting of albumin, globulin, and fibrinogen. More specifically, albumin may comprise bovine serum albumin (BSA).
[0054] For example, the hormone may include one or more hormones selected from the group consisting of hepatic growth hormone, follicle-stimulating hormone, luteinizing hormone, luteinizing hormone-releasing hormone, adrenocortical hormone and thyroid-stimulating hormone.
[0055] For example, the enzyme may comprise one or more enzymes selected from the group consisting of glucocerebrosidase, iduronate-2-sulfatase, alpha-galactosidase-A, alpha-agalsidase, alpha-L-iduronidase, butyrylcholinesterase, chitinase, glutamate decarboxylase, imiglucerase, lipase, uricase, platelet activating factor acetylhydrolase, neutral endopeptidase and myeloperoxidase.
[0056] For example, the antibody may comprise one or more antibodies selected from the group consisting of monoclonal antibodies, polyclonal antibodies and antibody fragments such as scFv, Fab, Fab', F(ab')2 and Fd.
[0057] For example, the growth factor may comprise one or more growth factors selected from the group consisting of platelet-derived growth factor, epithelial growth factor, epidermal growth factor, and nerve growth factor. Here, the nerve growth factor may be ciliary neurotrophic factor, axogenesis factor 1, or natriuretic peptide. cerebral, netrin, neutrophil inhibitory factor, neurotrophic factor, neuturine, etc.
[0058] For example, the transcriptional regulatory factor is a factor that binds to RNA polymerase in such a way as to regulate transcription and may include a transcription complex that binds to a transcription pre-initiation complex or a promoter. By way of example, the transcription complex may be a TATA-binding protein that binds to a TATA box of T DNA, and may be specifically TFIIA, TFIIB, TFIID, etc.
[0059] For example, the blood clotting factor may be factor I (fibrinogen), factor II (prothrombin), factor V (proaccelerin or labile factor), factor VII (proconvertin), factor VIII (antihemophilic factor A), factor IX (antihemophilic factor B), factor X (Stuart-Prower factor), factor XI (history of plasma thromboplastin (PTA)), factor XIII (fibrin-stabilizing factor), etc.
[0060] For example, the vaccine is not particularly limited as long as it is a vaccine capable of treating a human body, and any such vaccine can be applied. As an example, the vaccine could be a vaccine antigen derived from a virus.
[0061] For example, the differentiation cluster can act as a ligand that activates a receptor. According to a specific example, the differentiation cluster can be a CD marker applicable to stem cells, leukocytes, etc.
[0062] For example, the receptor antagonist may be a protein that acts on receptor molecules in vivo in order to inhibit or suppress the functions of neurotransmitters, hormones, etc.
[0063] For example, the peptide may be a growth hormone-releasing peptide, glucagon-like peptides (GLP-1, etc.), a macrophage peptide, a thrombin receptor activator peptide, a fibrin-binding peptide, a pancreatic polypeptide, a gastrin-releasing peptide, a plant peptide, acetyl hexapeptide-8, oligopeptide-1 (EGF), or biomimetic peptides such as tripeptide-1. According to a specific example, the peptide may be one or more peptides selected from peptides isolated from camellia flower extract, peptides isolated from wheat extract, peptides isolated from soybean extract, peptides isolated from oat extract, etc.
[0064] For example, the extracellular matrix may comprise one or more matrices selected from the group consisting of collagen, gelatin, elastin, osteocalcin, fibrinogen, fibromodulin, tenascin, laminin, osteopontin, osteonectin, perlecan, versicane, von Willebrand factor and vitronectin.
[0065] For example, nucleic acid can be DNA, RNA, an oligonucleotide, etc.
[0066] For example, the lipid can be a sphingolipid, a ceramide, a cholesterol, a cholesterol ester, a triglyceride, a phospholipid and a fatty acid, etc. According to a specific example, the lipid can be camellia oil.
[0067] For example, the carbohydrate can be sugars, oligosaccharides, polysaccharides, etc.
[0068] For example, the medicinal product may include at least one medicinal product selected from among antibiotics, anticancer agents, anti-inflammatories, antivirals and antibacterials. According to a specific example, the antibiotic may include one or more antibiotics selected from the group consisting of tetracycline, minocycline, doxycycline, ofloxacin, levofloxacin, ciprofloxacin, clarithromycin, erythromycin, cefaclor, cefotaxime, imipenem, penicillin, gentamicin, streptomycin and vancomycin, or derivatives thereof. According to a specific example, the anticancer drug may include one or more anticancer drugs chosen from the group consisting of methotrexate, carboplatin, Taxol, cisplatin, 5-fluorouracil, doxorubicin, etoposide, paclitaxel, camptothecin and cytosine arabinoside, or derivatives thereof.In a specific example, the anti-inflammatory agent may include one or more anti-inflammatory agents chosen from the group consisting of indomethacin, ibuprofen, ketoprofen, piroxicam, flurbiprofen, and diclofenac, or derivatives thereof. In a specific example, the antiviral agent may include at least one antiviral agent chosen from acyclovir and ribavirin, or derivatives thereof. In a specific example, the antibacterial agent may include at least one antibacterial agent chosen from ketoconazole, itraconazole, fluconazole, amphotericin B, and griseofulvin, or derivatives thereof.
[0069] A phytochemical is a chemical substance produced by a plant and may include, for example, one or more substances selected from the group consisting of flavonoids, carotenoids, phenolic acids, glucosinolates, vitamin derivatives, saponins, alkaloids, and lignans. In a specific example, a flavonoid may be one or more flavonoids selected from quercetin, kaempferol, catechin, anthocyanin, etc. In a specific example, a carotenoid may be at least one carotenoid selected from the group consisting of beta-carotene, lycopene, lutein, zeaxanthin, etc. In a specific example, a phenolic acid may be one or more phenolic acids selected from caffeic acid, ferulic acid, etc. According to a specific example, the vitamin derivative could be bakuchiol, tocopheryl acetate, etc. According to a specific example, saponin can be ginsenoside, madecassoside, titrated extract of Centella asiatica, soyasaponin, etc.
[0070] According to one embodiment of this disclosure, the insertion of multiple bioactive substances into exosomes can be carried out while homogenizing a mixture of multiple bioactive substances and exosomes using a homogenizer.
[0071] Homogenization can be carried out at a pressure of 800 to 1200 bar, preferably 900 to 1100 bar, more preferably 950 to 1050 bar, even more preferably 980 to 1020 bar, even more preferably 990 to 1010 bar, and preferably 1000 bar. When homogenization is carried out at less than 800 bar, an insufficient amount of the bioactive substances is inserted into the exosomes, and when homogenization is carried out at more than 1200 bar, there is a problem whereby the structure of the exosomes is destroyed.
[0072] Homogenization can be carried out at 5 to 50°C, preferably at 10 to 40°C, and more preferably at 15 to 30°C. When homogenization is carried out at less than 5°C, the membrane fluidity of the exosomes decreases and, thus, an insufficient quantity of the bioactive substances to be inserted is available, and when homogenization is carried out at 50°C or more, there is a problem whereby the structure of the bioactive substances to be inserted into the exosomes is modified, so that they can no longer function as bioactive substances.
[0073] Homogenization can be carried out by repeating it once or several times, preferably two to four times, and more preferably three times; however, even when homogenization is carried out more than four times, the quantity of bioactive substances inserted into the exosomes does not increase, and this is therefore neither economical nor efficient.
[0074] Step (S30) is a niosome preparation step.
[0075] In this disclosure, the niasome refers to a vesicle based on a nonionic surfactant, which is a microparticle having a hydrophilic space formed within it and having a closed lipid bilayer membrane that exhibits hydrophobic properties on the outside.
[0076] The niosome can be formed by comprising a nonionic surfactant, a stabilizer, and a solvent. Furthermore, the niosome can be formed by further comprising an auxiliary emulsifier in addition to the ingredients described above.
[0077] In this disclosure, the term "nonionic surfactant" refers to a surfactant that is not dissociated into ions, and is also referred to as a nonionic active agent or a nonionic surfactant. The properties of a nonionic surfactant, unlike those of an ionic surfactant, allow for free mixing with other surfactants or electrolytes. The nonionic surfactant is harmless for the skin and has characteristics such as thickening of a shampoo base, improved low temperature stability and excellent cleansing action while generating less foam, and can therefore be used for various purposes, such as as a dispersant, emulsifier, detergent and dyeing aid.
[0078] The nonionic surfactant may have a hydrophilic-lipophilic balance (HLB) of 11 to 18, specifically 13 to 16, but not necessarily limited to this, and a nonionic surfactant having emulsifying (or emulsifying agent) properties, more specifically water-soluble emulsifying properties, may be used.
[0079] In addition, the non-ionic surfactant is preferably biodegradable.
[0080] Specifically, polyglyceryl esters, sorbitan esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene alkyl ethers, poloxamers, or mixtures thereof may be used as a nonionic surfactant, but not limited to them, and a nonionic surfactant having similar properties may be used.
[0081] The polyglyceryl ester may be, for example, polyglyceryl-3 oleate, polyglyceryl-4 oleate, polyglyceryl-6 oleate, polyglyceryl-10 oleate, polyglyceryl-10 stearate, polyglyceryl-3 stearate, polyglyceryl-4 laurate, polyglyceryl-4 caprate, polyglyceryl-6 caprylate, etc., but the type thereof is not necessarily limited to these, and a suitable type capable of dissolving cholesterol in an aqueous solvent may be chosen.
[0082] The sorbitan ester may be, for example, sorbitan monolaurate (or Span 20), sorbitan monostearate (or Span 60), sorbitan monooleate, etc., but the type thereof is not necessarily limited to these, and a suitable type capable of dissolving cholesterol in an aqueous solvent may be chosen.
[0083] The polyoxyethylene sorbitan fatty acid ester may be, for example, polyoxyethylene (20) sorbitan monolaurate (Tween 20), polyoxyethylene (20) sorbitan monostearate (Tween 60), polyoxyethylene (20) sorbitan monooleate (Tween 80), etc., but the type thereof is not necessarily limited to these, and a suitable type capable of dissolving cholesterol in an aqueous solvent may be chosen.
[0084] Polyoxyethylene alkyl ether may include, for example, polyoxyethylene lauryl ether (4) (Brij 30), polyoxyethylene lauryl ether (23) (Brij 35), polyoxyethylene stearyl ether (20) (Brij 78), etc., but the type thereof is not necessarily limited to these, and a suitable type capable of dissolving cholesterol in an aqueous solvent may be chosen.
[0085] In the present disclosure, the stabilizer is added to form an internal phase of the niosome and to stabilize the niosome. By way of example of such a stabilizer, one or more stabilizers selected from the group consisting of betaine, the Butylene glycol, polyhydric alcohols, organic acids, organic salts, sugar and protein complexes, and polyols including glycerin, propylene glycol and dipropylene glycol may be used, and may preferably include glycols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol and polyethylene glycol; polyhydric alcohols such as 1,2-hexanediol; glycerols such as glycerin, diglycerin and polyglycerin; saccharides such as sorbitol, mannitol, sugar, starch syrup and lactitol; water-soluble polymers such as guar gum, sodium chondroitin sulfate, sodium hyaluronate, sodium alginate, methylcellulose, hydroxymethylcellulose, carboxyvinyl polymer, polyvinyl alcohol, polyvinylpyrrolidone, alkylated vinyl carboxylic polymer, sodium polyacrylate, gum arabic and carrageenan;salts such as sodium chloride, magnesium chloride and sodium lactate, and similar ones, and, among these, it is best to include glycerin.
[0086] The stabilizer may be in an amount of 100 parts by weight, 20 parts by weight, 300 parts by weight, 400 parts by weight, 500 parts by weight, 600 parts by weight, 700 parts by weight, 800 parts by weight, 900 parts by weight, 1000 parts by weight, or parts by weight within a range between any two of the preceding values, based on 100 parts by weight of the nonionic surfactant. Preferably, the stabilizer may be in an amount of 200 parts by weight, 300 parts by weight, 400 parts by weight, 500 parts by weight, or parts by weight within a range between any two of the preceding values. For example, the range could be 200 to 500 parts by weight, 300 to 500 parts by weight, 300 to 400 parts by weight, etc.When the amount of stabilizer added is less than 100 parts by weight, the internal phase of the niosomes is not properly formed and the stability of the niosomes is poor, and, when the amount added exceeds 1000 parts by weight, there is a disadvantage whereby the viscosity of the composition increases greatly, which makes subsequent fusion with vegan exosomes difficult.
[0087] In the present disclosure, the auxiliary emulsifier is a substance that assists the surfactant so that a hydrophilic substance and a hydrophobic substance are mixed in a solvent without phase separation, and is not limited in terms of type, but may be higher alcohols (cetyl alcohol, stearyl alcohol, myristyl alcohol, behenyl alcohol, cetostearyl alcohol, cetearyl alcohol), fatty acid esters (isopropyl myristate, cetyl octanoate, oleyl oleate, isobutyl adipate, cetyl 2-ethylhexanoate, N-alkyl glycol monoisostearate, glyceryl stearate), or a lecithin, and preferably comprises a lecithin.
[0088] Lecithin refers to a natural or synthetic lecithin that can be appropriately purified. Appropriate lecithin includes, but is not limited to, lecithin derived from eggs or soy. More appropriate lecithin includes, but is not limited to, dihexanoyl-L-alpha-lecithin, dioctanoyl-L-alpha-lecithin, didecanoyl-L-alpha-lecithin, didodecanoyl-L-alpha-lecithin, ditodecanoyl-L-alpha-lecithin, ditetradecanoyl-L-alpha-lecithin, dihexadecanoyl-L-alpha-lecithin, dioctadecanoyl-L-alpha-lecithin, dioleoyl-L-alpha-lecithin, dilinoleoyl-L-alpha-lecithin, and alpha-palmitol.
[0089] Lecithin is generally a mixture of fatty acid diglycerides linked to the choline ester of phosphoric acid, and may include varying amounts of other compounds depending on the isolation process. Typically, commercial lecithin is a mixture of acetone-insoluble phosphatides. Preferably, lecithin is obtained from seeds including soybeans and corn, preferably soybeans, using processes well known in the art. Lecithin obtained from soybeans is referred to as "soybean lecithin" in this disclosure.
[0090] The auxiliary emulsifier may be contained in an amount of 100 to 500 parts by weight, preferably 200 to 400 parts by weight, and more preferably 300 to 400 parts by weight, based on 100 parts by weight of the nonionic surfactant. When the auxiliary emulsifier content is below the above range, there is a problem that the stability of the ionosome is reduced, and when the content exceeds the aforementioned range, there is a problem that the user experience of the topical skin preparation and the cosmetic composition is impaired.
[0091] The ingredients may be added to a solvent and stirred so as to be completely mixed. In this case, the solvent used is not limited in this disclosure as long as it is a water-soluble solvent, and preferably includes lower alcohols such as ethanol, saline in phosphate buffer (PBS), physiological saline, or water.
[0092] The solvent may be comprised in an amount of 180 to 220 parts by weight, preferably 190 to 210 parts by weight, and more preferably 200 parts by weight, based on 100 parts by weight of the non-ionic surfactant.
[0093] In this disclosure, the niosome can be prepared by mixing the nonionic surfactant, stabilizer, and solvent, or by further mixing in an auxiliary emulsifier, and subjecting the mixture to high-pressure homogenization. For example, the niosome can be prepared by mixing the nonionic surfactant, stabilizer, and solvent, and homogenizing and dispersing the mixture at 600 to 800 bar with a high-pressure homogenizer. For example, the niosome can be prepared by mixing the nonionic surfactant, stabilizer, and emulsifier. The auxiliary agent and solvent are then homogenized and dispersed at 600–800 bar using a high-pressure homogenizer. In this case, temperature and time are not particularly limited and can be homogenized by adjusting them appropriately according to the niosome's ingredient content. The niosome prepared as described above exhibits higher membrane fluidity than a conventionally prepared niosome, and thus fusion with the vegan exosomes described above is easily achieved. Multiple bioactive substances inserted into the vegan exosomes can then be readily incorporated and retained within the fused hybrid nanocomposite.
[0094] Furthermore, homogenization can be carried out by repeating it once or several times, preferably two to four times, so that the nonionic surfactant, stabilizer and solvent, or auxiliary emulsifier included further, can be homogenized and dispersed uniformly.
[0095] In the present disclosure, the average particle diameter of the niosome is not particularly limited, but the average particle diameter can satisfy a value of 10 to 200 nm. Since the average particle diameter of the niosome affects the average particle diameter of a finally prepared hybrid nanocomposite, when the average particle diameter of the niosome is less than the aforementioned range, there is a problem whereby the quantity of the multiple bioactive substances, which are active ingredients inserted into the finally prepared hybrid nanocomposite, is too low, and, when the average particle diameter of the niosome exceeds the aforementioned range, there is a problem whereby the size of the finally prepared hybrid nanocomposite is large, and thus reduces skin permeability.
[0096] Step (S40) is a step of mixing vegan exosomes into which the multiple bioactive substances of step (S20) are inserted with the niosomes prepared in step (S30), and of ultrasonic treatment of the latter in order to fuse the vegan exosomes and the niosomes so as to form the hybrid nanocomposite.
[0097] The mixing of vegan exosomes and niosomes can be carried out at a particle number of 0.1 to 2:0.1 to 2, preferably at a particle number of 0.8 to 1.2:0.8 to 1.2, and preferably at a particle number of 1:1. Outside the aforementioned range, there is a problem whereby the fusion efficiency decreases due to the fact that a content of either of the vegan exosomes or niosomes is high.
[0098] The fusion of vegan exosomes and niosomes can be carried out by ultrasonic treatment. Ultrasonic treatment is an easy and simple process regardless of pH and temperature conditions and can increase the fusion efficiency compared to a fusion process by simple mixing and stirring Vegan exosomes and niosomes, and a process for mixing and fusing cationic lipids and auxiliary lipids with a mixture of vegan exosomes and niosomes. The efficiency of the fusion relates to the size, uniformity, and stability of the hybrid nanocomposite.
[0099] Ultrasonic treatment can be carried out under conditions of 30 to 50 kHz, preferably 35 to 45 kHz, more preferably 38 to 42 kHz, and preferably 40 kHz for 8 to 12 minutes, preferably 9 to 11 minutes, and preferably 10 minutes.
[0100] The hybrid nanocomposite formed by said ultrasonic treatment forms a bilayer or a trilayer by irregularly arranging a portion of the bilayer constituting the vegan exosomes and a portion of the bilayer constituting the niosomes, and the multiple bioactive substances inserted into the vegan exosomes are inserted into the hybrid nanocomposite. In this case, 'insertion' refers to the fact that the bioactive substances are positioned inside the hybrid nanocomposite or that the bioactive substances are attached to a surface of the hybrid nanocomposite or between the membranes of the hybrid nanocomposite by a chemically covalent or non-covalent bond. Accordingly, in the present description, the expressions 'hybrid nanocomposite' or 'hybrid nanocomposite in which exosomes and niosomes are fused' are used to mean 'comprising the insertion of the multiple bioactive substance'.
[0101] In the present disclosure, the average particle diameter of the nanocomposite in which the vegan exosomes and niosomes are fused is not particularly limited, but the average particle diameter can satisfy a value of 100 to 200 nm. When the average particle diameter of the hybrid nanocomposite is less than the aforementioned range, there is a problem whereby an insufficient quantity of the multiple bioactive substances to be inserted is present, and, when the average particle diameter of the hybrid nanocomposite exceeds the aforementioned range, there is a problem whereby, due to its large size, in vivo permeation is difficult, which reduces the in vivo delivery of the multiple inserted bioactive substances.
[0102] In the present disclosure, the hybrid nanocomposite in which vegan exosomes and niosomes are fused exhibits a uniformity of 0.1 to 0.2, preferably 0.10 to 0.15, and preferably 0.10 to 0.14, and thus exhibits a uniform size.
[0103] In the present disclosure, the hybrid nanocomposite in which vegan exosomes and niosomes are fused exhibits a zeta potential of -26.80 to -27.50, preferably a zeta potential of -27.00 to -27.50.
[0104] In the present disclosure, the hybrid nanocomposite in which vegan exosomes and niosomes are fused is sufficiently stable to be stored for an extended period at 0 to 50°C without any change in mean particle diameter and uniformity. As a specific example, the hybrid nanocomposite of the present disclosure exhibited the same particle number, zeta potential, and mean particle diameter as on day 0 of preparation, even when stored at 0 to 50°C for 4 weeks.
[0105] According to another aspect, the present disclosure proposes a hybrid nanocomposite in which vegan exosomes and niosomes are fused, prepared by the process described above.
[0106] The hybrid nanocomposite according to the present disclosure in which vegan exosomes and niosomes are fused forms a bilayer or a trilayer by irregularly arranging part of a bilayer which constitutes vegan exosomes and part of a bilayer which constitutes niosomes, and the multiple bioactive substances to be delivered to a subject are present on a surface of the hybrid nanocomposite, between the membranes of the hybrid nanocomposite, and inside the hybrid nanocomposite, and thus constitutes a carrier which delivers the multiple bioactive substances in vivo.
[0107] In this disclosure, the subject matter may be animals such as horses, cows, dogs, sheep, including humans, but not necessarily limited to them.
[0108] As described above, multiple bioactive substances are two or more substances present in living organisms, such as plants, animals or microorganisms, and which affect various physiological activities, and the substances may include substances chemically synthesized or produced by recombinant microorganisms so as to have chemical structures or constituent components identical to those of substances present in living organisms at 80% or more, preferably 90% or more, while affecting physiological activities at levels equivalent to those of substances present in living organisms.
[0109] The product may be dispensed by formulation into a pharmaceutical formulation, for example, a powder, granule, extended-release granule, liquid, emulsion, suspension, spirit, tablet, extended-release tablet, hard capsule, soft capsule, extended-release capsule, pill, plaster, lotion, paste, spray, inhalant, patch, aerogel, topical preparation, etc., but not necessarily limited to these. The topical preparation may have a formulation such as a cream, a gel, a patch, a spray, an ointment, a plaster, a lotion, a liniment, a paste or a poultice.
[0110] In addition, delivery may be effected by formulation in a cosmetic formulation, for example, in the form of a film, an emulsion, a cream, a sunscreen, a foundation, an essence, a gel, a pad, a mask, a foaming cleanser, a body wash, a softening lotion, an eyeliner, a shampoo, a mouthwash, a soap, a hair fixative, a hair growth promoter, a styling cream, a styling gel, a lubricant, a toothpaste, an aerosol and a transdermal patch, without however being necessarily limited to them.
[0111] The hybrid nanocomposite in which vegan exosomes and niosomes are fused may have an average particle diameter of 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, 150 nm, 160 nm, 170 nm, 180 nm, 190 nm, or 200 nm, or within a range between any two of the preceding values. When the average particle diameter of the hybrid nanocomposite is less than 100 nm, there is a problem whereby the quantity of the multiple bioactive substances to be inserted is too small, and when the average particle diameter of the hybrid nanocomposite exceeds 200 nm, there is a problem whereby, due to its large size, in vivo permeation is difficult, which reduces the in vivo delivery of the multiple bioactive substances inserted into the hybrid nanocomposite.
[0112] The hybrid nanocomposite in which vegan exosomes and niosomes are fused exhibits a uniformity of 0.1 to 0.2, preferably of 0.10 to 0.15, and preferably of 0.10 to 0.14, and thus exhibits a uniform size.
[0113] In the present disclosure, the hybrid nanocomposite in which vegan exosomes and niosomes are fused exhibits a zeta potential of -26.80 to -27.50, preferably a zeta potential of -27.00 to -27.50.
[0114] The hybrid nanocomposite in which vegan exosomes and niosomes are fused is sufficiently stable to be stored for extended periods at 0 to 50°C without any change in mean particle diameter or uniformity. As a specific example, the hybrid nanocomposite of this disclosure exhibited the same particle number, zeta potential, and mean particle diameter as on day 0 of preparation, even when stored at 0 to 50°C for 4 weeks.
[0115] According to another aspect, the present disclosure proposes a composition intended to deliver bioactive substances, comprising the hybrid nanocomposite in which vegan exosomes and niosomes are fused and in which the multiple bioactive substances are inserted.
[0116] In the delivery composition, all the preceding descriptions can be applied as such to the hybrid nanocomposite and to the multiple bioactive substances inserted therein.
[0117] Delivery consists of providing the multiple bioactive substances to the skin or tissues of a subject. More specifically, delivery refers to providing the multiple bioactive substances to the skin or tissues of animals such as horses, cows, dogs, sheep, cats, and monkeys, including humans, in various formulations such as the pharmaceutical formulation described above, the topical preparation formulation, the cosmetic formulation, or the food formulation. The pharmaceutical formulation, the topical preparation formulation, the cosmetic formulation, or the food formulation are as described in this description.
[0118] According to one embodiment, when the multiple bioactive substances are PDRN, camellia oil and a peptide derived from the camellia flower, the multiple bioactive substances are delivered to the skin of a subject by a hybrid nanocomposite in which the multiple bioactive substances are inserted, and thus simultaneously exhibit cell regeneration effects, antioxidant effects, anti-aging effects, wrinkle improvement, brightening, skin volume increase and hydration effects according to the PDRN, camellia oil and the peptide derived from the camellia flower.
[0119] According to another embodiment, when the multiple bioactive substances are ceramide and tocopheryl acetate, cell barrier strengthening effects, antioxidant effects and anti-inflammatory effects depending on the hybrid nanocomposite in which the multiple bioactive substances are inserted can be presented simultaneously.
[0120] According to another aspect, the present disclosure proposes a composition comprising, as an active ingredient, a hybrid nanocomposite in which vegan exosomes and niosomes are fused and in which the multiple bioactive substances are inserted.
[0121] The composition exhibits effects depending on the type of multiple bioactive substances inserted into the nanocomposite, which is an active ingredient. In one embodiment, when the multiple bioactive substances are two or more antibiotics, a hybrid nanocomposite in which the two or more antibiotics are inserted constitutes a composition and exhibits the effects of antibiotics in a subject depending on the administration of the composition. In another embodiment, when the multiple bioactive substances are PDRN, camellia oil, and a peptide derived from the camellia flower, a hybrid nanocomposite in which the multiple bioactive substances are inserted constitutes a composition and exhibits effects depending on the PDRN, camellia oil and camellia flower derived peptide in a subject according to the administration of the composition.
[0122] Administration means the introduction of a predetermined substance into a subject by an appropriate method, and a route of administration of the composition can be any general route as long as it is capable of reaching a target tissue.
[0123] When the composition is a cosmetic composition, a pharmaceutical composition or a topical composition for cutaneous application, the nanocomposite in which the vegan exosomes and niosomes are fused and in which the multiple bioactive substances constituting the active ingredients of the composition are inserted may be comprised in an amount of 0.0001 to 20% by weight, preferably 0.0001 to 15% by weight, preferably 0.001 to 15% by weight, and preferably 0.001 to 10% by weight, based on a total weight percentage of the composition.Furthermore, when the composition is a food composition, the hybrid nanocomposite in which vegan exosomes and niosomes are fused and in which the multiple bioactive substances that constitute the active ingredients of the composition are inserted may be comprised in an amount of 0.0001 to 100% by weight, preferably 0.0001 to 90% by weight, preferably 0.001 to 90% by weight, and preferably 0.001 to 80% by weight, based on a total weight of the composition.
[0124] Depending on a specific aspect, the composition may be a cosmetic composition.
[0125] In addition to the hybrid nanocomposite in which vegan exosomes and niosomes are fused and into which the multiple bioactive substances are inserted, the cosmetic composition may further comprise ingredients commonly used in cosmetic compositions. For example, the cosmetic composition may include common adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances, as well as carriers.
[0126] The cosmetic composition may be prepared in any formulation commonly prepared in the technique. For example, the cosmetic composition may be formulated as a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, cleansing product containing a surfactant, oil, powder foundation, emulsion foundation, wax foundation, or spray, etc. More specifically, the cosmetic composition may be prepared in a formulation such as a nourishing cream, astringent lotion, softening lotion, lotion, essence, nourishing gel, or massage cream, etc. However, the cosmetic composition is not particularly limited to these.
[0127] When the formulation of the cosmetic composition is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth gum, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc. may be used as a carrier ingredient.
[0128] When the formulation of the cosmetic composition is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or a polyamide powder may be used as a carrier ingredient, and, particularly when the formulation is a spray, it may further comprise a propellant such as a chlorofluorohydrocarbon, propane / butane or dimethyl ether.
[0129] When the formulation of the cosmetic composition is a solution or an emulsion, a solvent, a solubilizing agent or an emulsifying agent may be used as a carrier ingredient. For example, water, ethanol, 1'-isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, aliphatic esters of glycerol, polyethylene glycol or fatty acid esters of sorbitan may be used.
[0130] When the formulation of the cosmetic composition is a suspension, liquid diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylenated sorbitol ester and polyoxyethylenated sorbitan ester, as well as microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth gum, etc., may be used as carrier ingredients.
[0131] When the formulation of the cosmetic composition is a cleansing product containing a surfactant, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, an imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, a fatty acid glyceride, fatty acid diethanolamide, vegetable oil, a lanolin derivative or an ethoxylated glycerol fatty acid ester, etc. may be used as a carrier ingredient.
[0132] According to a specific aspect, the composition may be a pharmaceutical composition. More specifically, the composition may be a pharmaceutical composition intended to prevent or treat skin diseases. The skin disease includes, but is not limited to, one or more diseases selected from the group consisting of atopic dermatitis, contact dermatitis, seborrheic dermatitis, psoriasis, acne, urticaria, allergic purpura, melasma, shingles, herpes simplex, folliculitis, and skin cancer.
[0133] A pharmaceutical composition means a composition prepared for the purpose of preventing or treating diseases and may be formulated and used in various forms according to a conventional process. For example, a pharmaceutical composition may be formulated as an oral formulation such as a powder, granule, tablet, capsule, suspension, emulsion, syrup, or aerosol, and may be used by being formulated as a parenteral formulation with the aid of diluents or excipients such as lubricants, wetting agents, flavorings, emulsifiers, suspending agents, preservatives, surfactants, etc. Furthermore, a pharmaceutical composition may be formulated and used as an injection, a topical preparation, or a topical preparation for the skin.
[0134] Furthermore, according to each formulation, the pharmaceutical composition can be prepared by further comprising a pharmaceutically acceptable carrier known in the art, such as buffers, analgesic agents, solubilizing agents, isotonic agents, stabilizers, bases, etc.
[0135] As used in this disclosure, the term "pharmaceutically acceptable carrier" may refer to a carrier or diluent that does not irritate a living organism or alter the biological activity or characteristics of an administered active ingredient. The type of carrier that may be used in this disclosure is not particularly limited, and any carrier may be used provided that it is commonly used in the relevant technical field and is pharmaceutically acceptable. Non-limiting examples of carriers include saline, sterile water, Ringer's solution, buffered saline, albumin injection, dextrose solution, maltodextrin solution, glycerol, ethanol, etc. These may be used alone or in a mixture of two or more types. The carrier may be of non-natural origin.
[0136] The pharmaceutical composition can be administered in a pharmaceutically effective amount. The pharmaceutically effective amount means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment and not excessive to the point of causing side effects, and an effective dose level can be determined on the basis of factors such as the patient's health status, the type and severity of a disease, the activity of a drug, sensitivity to a drug, a method of administration, the timing of administration, a route of administration and rate of excretion, the duration of treatment, drugs used in combination or simultaneously, and other factors well known in the medical field.More specifically, the dose is generally 0.01 mg to 5000 mg per day per kg of body weight of an administering subject, and can be administered once a day to several times a day. in divided doses at predetermined time intervals as decided by a doctor or pharmacist, but not limited to this.
[0137] According to a specific aspect, the composition may be a topical composition for cutaneous application.
[0138] The topical composition for cutaneous application may be formulated containing a cosmetically or dermatologically acceptable medium or base. The topical composition for cutaneous application may be provided in any formulation suitable for topical application, such as a solution, gel, solid, anhydrous paste, emulsion obtained by dispersing an oily phase in an aqueous phase, suspension, microemulsion, microcapsule, microgranule, or ionic (liposome) and nonionic vesicular dispersant, or in the form of a cream, film, lotion, powder, ointment, spray, mask, or corrective stick. The topical composition for cutaneous application may also be used in the form of a foam or as an aerosol composition further comprising a compressed propellant.These compositions can be prepared according to conventional methods in art.
[0139] In addition, the topical composition for cutaneous application may contain a fatty substance, an organic solvent, a solubilizing agent, a thickener, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a perfume, a surfactant, water, an ionic or non-ionic emulsifier, a filler, a metal ion sequestering agent, a chelating agent, a preservative, a vitamin, a blocking agent, a wetting agent, an essential oil, a colorant, a pigment, a hydrophilic or lipophilic active agent, a lipid vesicle, or an adjuvant commonly used in the cosmetic or dermatological field, as well as any other ingredient commonly used in cosmetics. The adjuvant is introduced in an amount generally used in the cosmetic or dermatological field.
[0140] According to a specific aspect, the composition may be a food composition.
[0141] The food composition may include all foods in the ordinary sense, and may be used interchangeably with terms known in the art, such as "functional food", "natural functional food", etc.
[0142] When the food composition is used as a food additive, the hybrid nanocomposite in which vegan exosomes and niosomes are fused and in which multiple bioactive substances are inserted can be added as is or can be used in conjunction with other foods or food ingredients, and can be used appropriately according to conventional processes. A mixing quantity of the active ingredient can be determined appropriately formulated for the intended use (prevention, health, or therapeutic treatment), and may also include site-appropriate dietary supplement additives. Since the composition of this disclosure is not only a substance derived from a natural product but has also been confirmed safe through human safety testing, there are no significant limitations on the quantity of the mixture.
[0143] According to another aspect, the present disclosure relates to a method for ensuring physiological activity induced by multiple bioactive substances by administering to a subject the hybrid nanocomposite in which vegan exosomes and niosomes are fused and in which the multiple bioactive substances are inserted in order to deliver the multiple bioactive substances to the subject.
[0144] All the preceding descriptions can be applied as such to the hybrid nanocomposite, to the multiple bioactive substances inserted therein, and to the physiological activity elicited by the multiple bioactive substances.
[0145] As described above, the subject may be a horse, a cow, a dog, a sheep, a cat or a monkey, including, but not limited to, a human.
[0146] Administration means the introduction of a predetermined substance into a subject by an appropriate method, and a route of administration of the composition may be any general route provided that it is capable of reaching a target tissue. For example, administration may be intraperitoneal, intravenous, intramuscular, subcutaneous, intradermal, oral, topical, intranasal, pulmonary, or rectal, but is not limited to these. Preferably, administration may be subcutaneous, intradermal, or topical.
[0147] BENEFICIAL EFFECTS
[0148] The hybrid nanocomposite in which vegan exosomes and niosomes are fused according to the present disclosure is a biocompatible carrier that overcomes the ethical and immunological limitations of conventional animal-derived exosome-based technologies, is capable of efficiently delivering complex bioactive effects because one or more bioactive substances are stably incorporated within it, and constitutes a novel carrier capable of maximizing, through the fusion of exosomes and niosomes, not only permeability and stability, but also a sustained-release effect. Consequently, the hybrid nanocomposite can be usefully employed in various formulations in cosmetics, pharmaceuticals, topical preparations, food, etc., as a carrier for multiple bioactive substances. Brief description of the drawings
[0149] Fig. 1 is a view that schematically illustrates a structure of a hybrid nanocomposite in which vegan exosomes and niosomes are fused and in which multiple bioactive substances are inserted.
[0150] Fig. 2 is a view that illustrates a process for preparing a hybrid nanocomposite in which vegan exosomes and niosomes are fused and which has multiple bioactive substances according to an embodiment of the present disclosure.
[0151] Fig. 3 is a view of the measurement of the particle sizes of each of the exosomes of Example Preparation 2, the niosomes of Example 4 and of a hybrid nanocomposite of Example Preparation 5 by dynamic light scattering (DLS), and of the comparison of these according to an embodiment of the present disclosure.
[0152] The [Fig.4] is an electrophoresis result which confirms that a bioactive substance is inserted into a hybrid nanocomposite in which vegan exosomes and niosomes are fused, prepared according to an embodiment of the present disclosure.
[0153] Fig. 5 is a fluorescence image analysis result which confirms that the hybrid nanocomposite prepared according to an embodiment of the present disclosure is a complex formed by fusion of vegan exosomes and niosomes.
[0154] DETAILED DESCRIPTION OF THE IMPROVEMENTS
[0155] The following are examples of this disclosure described in detail to facilitate understanding of this disclosure. However, various modifications and changes may be made to the examples in this disclosure, and it should be understood that the scope of the disclosure is not limited to the following examples. The examples in this disclosure are provided to the person skilled in the art for a more complete description of this disclosure.
[0156] Example 1: Extraction and purification of vegan exosomes
[0157] Lactobacillus rhamnosus BS Pro-8 (registration number: KCTC 15876 BP) was cultured in modified MRS medium under anaerobic conditions at 37°C for 3 days. After completion of the culture, the culture medium was centrifuged at 5000 rpm for 30 minutes and filtered through a 0.22 µm funnel filter to separate and remove bacterial cells, cell debris, etc. A supernatant was subjected to 100 kDa size reduction (MWCO) (PES membrane, Merck) by TFF to purify and concentrate high-purity exosomes. Following confirmation of exosome sizes by dynamic light scattering (DLS, ELSZ-2000ZS, Otsuka Electronics), an average exosome size of approximately 187.7 nm.
[0158] Example 2: preparation of a bioactive substance
[0159] Polydeoxyribonucleotide (PDRN), camellia oil, and a plant-derived peptide were prepared as the bioactive substance. More specifically, high-purity PDRN (>90%) purchased from HTL was used as the PDRN. The camellia oil was prepared by extracting camellia oil from camellia seeds by a cold-pressing process and then refining the camellia oil using activated carbon and bentonite. The peptide was obtained as a crude peptide by softening camellia flowers in hot water (80°C, 3 hours) and then treating the softened camellia flowers with an enzyme (1% protamax of the substrate, 50°C, 6 hours). Following measurement using MALDI-TOF mass spectrometry (MALDI TOF Voyager DE-STR, Applied Biosystems, USA), it was confirmed that a molecular weight of the peptide was approximately 1200 Da.
[0160] Example 3: preparation of vegan exosomes into which multiple bioactive substances are inserted
[0161] The PDRN, camellia oil, and peptide of Example 2 were mixed with the purified exosomes of Example 1, and the PDRN, camellia oil, and peptide were inserted into the exosomes using a high-pressure homogenizer under the conditions shown in Table 1. The reaction conditions are shown in Table 1, and the exosomes prepared under these conditions have been designated "Preparation Examples 1 to 3." By this process, exosomes in which the PDRN, camellia oil, and peptide are inserted were prepared.
[0162] [Tables 1] Homogenizer Pressure and Cycle Category: Example of preparation 1: 600 bar, 3 cycles; Example of preparation 2: 1000 bar, 3 cycles; Example of preparation 3: 1400 bar, 3 cycles
[0163] Example 4: Niosome preparation
[0164] 100 parts by weight of a biodegradable non-ionic surfactant from a series of esters Plant-derived polyglyceryl, 400 parts by weight of glycerin and 200 parts by weight of water were mixed and passed through a high-pressure homogenizer for 2 cycles at a pressure of 600 to 800 bar to prepare nanometer-sized niosomes.
[0165] Example 5: preparation of a hybrid nanocomposite in which vegan exosomes and niosomes are fused and in which multiple bioactive substances are inserted
[0166] Vegan exosomes into which the multiple bioactive substances are inserted, prepared by means of preparation examples 1 to 3, were added to the Niosomes prepared in Example 4 at a particle ratio of 1:1 were then subjected to an ultrasonic membrane fusion reaction (Sonies vibracell, 40 kHz, 10 minutes) to prepare a hybrid nanocomposite fused with the niosomes. The reaction conditions are shown in Table 2, and a schematic structure of this nanocomposite is illustrated in [Fig. 1].
[0167] [Tables2] Category: Hybrid conditions exosomes + niosomes Example of preparation 4 Example of preparation 1 + Example 4 Example of preparation 5 Example of preparation 2 + Example 4 Example of preparation 6 Example of preparation 3 + Example 4
[0168] Example 6: Measurement of a hybrid nanocomposite in which vegan exosomes and niosomes are fused
[0169] In order to confirm the stability under each condition of the hybrid nanocomposites of preparation examples 4 to 6 prepared in example 5, the particle numbers were measured using nanoparticle tracking analysis (NTA), and the particle sizes were measured by dynamic light scattering, and the result is shown in Table 3. The vegan exosomes of preparation example 2 were designated as the comparative example.
[0170] Sample preparation 2 had a size of 155.9 nm and a PI value of 0.141. Sample preparation 4 had a size of 183.5 nm and a PI value of 0.431. Sample preparation 5 had a size of 162.7 nm and a PI value of 0.125. Sample preparation 6 had a size of 32.3 nm and a PI value of 0.518. In the case of sample preparation 6, it was confirmed that all exosomes had been destroyed by a high-pressure environment and could not be incorporated with the niosomes, so that an average particle size and particle number did not form.
[0171] [Tables3] Category Example of p repair 2 Example of p repair 4 Example of p repair 5 Example of p repair 6 DLS (nm) 155.9 183.5 162.7 32.3 PI 0.141 0.431 0.125 0.518 Number of particles (particles / mL) 9.7E+10 1.25E+11 1.7E+11 4.5E+08
[0172] Example 7: Stability experiment of a hybrid nanocomposite in which vegan exosomes and niosomes are fused
[0173] In order to confirm the stability as a function of storage time and temperature of the hybrid nanocomposites of preparation examples 4 to 6 prepared in example 5, the particle numbers and zeta potentials of the hybrid nanocomposites of preparation examples 4, 5 and 6 were measured using nanoparticle tracking analysis and are shown in Tables 4 and 5, and the particle sizes were measured by dynamic light scattering and are shown in Table 6 and on [Fig.3].
[0174] [Tables4] Number of particles (particles / ml) Example of preparation n4 Example of preparation n5 Example of preparation 6 4°C 25°C 45°C 4°C 25°C 45°C 4°C 25°C 45°C Day 0 1.25E+11 1.7E+11 4.5E+08 Week 4 9.8E 3.1E 5.5E 1.7E 1.5E 1.9E 4E+ 3.8E 6.7E +11 +12 +12 +12 +12 +12 08 +08 +08
[0175] [Tables5] Zeta potential (mV) Example of preparation n4 Example of preparation n5 Example of preparation n6 4°C 25°C 45°C 4°C 25°C 45°C 4°C 25°C 45°C Day 0 -25.99 -27.27 -26.00 Week 4 -26.00 -25.45 -26.01 -26.50 -29.78 -25.88 -26.24 -26.48 -26.83
[0176] [Tableauxô] Particle size (nm) Example of preparation 4 Example of preparation 5 Example of preparation 6 4°C 25°C 45°C 4°C 25°C 45°C 4°C 25°C 45°C Day 0 163.9 146.6 35.7 Week 4 351.5 305.8 399.8 167.5 162.4 159.4 45.1 32.5 40.8
[0177] In the case of Example Preparation 4, it was confirmed that a separation had occurred over time, causing changes in the number and size of particles. In contrast, in the case of Example Preparation 5, it was confirmed that a stable structure had been maintained.
[0178] It has been confirmed that, when the pressure was too low, as in preparation example 4, homogenization was not achieved, resulting in instability and a failure to insert the bioactive substance, while, when the pressure was too high, as in preparation example 6, the exosomes were destroyed and did not fuse properly with the niosomes. This confirmed that the hybrid nanocomposite prepared under the conditions of preparation example 5 was the most stable.
[0179] Example 8: Safety confirmation experiment of a hybrid nanocomposite for human skin
[0180] 8-1. Preparation of a topical skin preparation comprising a hybrid nanocomposite
[0181] In order to confirm whether the hybrid nanocomposite in which vegan exosomes and niosomes are fused according to this disclosure is safe for human skin, a topical skin preparation comprising the nanocomposite of Example Preparation 5 was prepared with the ingredients and contents indicated in Table 7 below, and a skin safety verification experiment using it was performed.
[0182] For the preparation of the topical skin preparation, purified water, glycerin, and butylene glycol were mixed and dissolved at 70°C (aqueous phase portion), and the remaining ingredients, other than the three ingredients and trimethanolamine, were dissolved at 70°C (oil phase portion). The oil phase portion was added to the aqueous phase portion and stirred with a mixer-homogenizer (Tokushu Kika, Japan) to perform primary emulsification, and then trimethanolamine was finally added. After removing the bubbles generated in the mixed solution, it was cooled to room temperature to prepare the topical skin preparation.
[0183] [Tables7] Ingredient Content (%) Control Group Test Group Purified Water 72.0 67 Glycerin 8.0 8.0 Butylene glycol 4.0 4.0 Hybrid nanocomposite in which vegan exosomes and niosomes are fused 0 5.0 Caprylic / capric triglyceride 8.0 8.0 Squalane 5.0 5.0 Cetearyl glucoside 1.5 1.5 Sorbitan stearate 0.4 0.4 Cetearyl alcohol 1.0 1.0 Trimethanolamine 0.1 0.1 Total weight 100 100
[0184] 8-2. Primary skin irritation test
[0185] Whether or not the hybrid nanocomposite of Example Preparation 5, in which vegan exosomes and niosomes are fused, causes skin irritation was measured by performing a 24-hour occlusive patch on the backs of 30 healthy adults using each topical skin preparation prepared in Example 8-1.
[0186] For the patch procedure, a chamber (IQ Ultimate™) from Chemotechnique MB Diagnostics AB was used. 20 qL of each topical skin preparation were placed in the chamber and the occlusive patch was applied for 24 hours. A skin reaction was observed 30 minutes and 24 hours after patch removal, and the presence and degree of skin irritation were visually assessed according to evaluation criteria. After calculating an average skin reactivity according to the determination criteria in Table 8 based on Frosch & Kligman (1979) and the CTFA Guidelines (2007), the skin irritation of each topical skin preparation was evaluated using the following experimental formula 1 based on a classified skin reactivity by applying the Draize method.
[0187] [Experimental Formula 1]
[0188] Formula for calculating an average skin irritation index
[0189] E [(Grade x number of test subjects exhibiting a reaction) / (4; highest grade x total number of test subjects)] 4 - number of evaluations
[0190] [Tables8] Symbol Grade Irritation Assessment - 0 No reaction + 1 Mild but clearly visible erythema ++ 2 Clearly visible erythema with papules or edema +++ 3 Severe erythema with edema and papules ++++ 4 Severe erythema with edema and blisters
[0191] [Tables9] Skin Reactivity Skin Irritation Rating 0.00-0.25 Non-irritating 0.26-1.00 Slightly irritating 1.01-2.50 Moderately irritating 2.51-4.00 Severely irritating
[0192] [Tables 10 Test substance Number of test subjects exhibiting a reaction Average reactivity After 30 minutes After 24 hours 1st 2nd 3rd 4th 1st 2nd 3rd 4th Control group - - - - - - - - 0.00 Test group - - - - - 1 - - 0.00 Number of test subjects 30 30 30 30 30 30 30 30
[0193] In Table 10, no irritation reaction was observed in the control group or the test group. When calculated according to the formula described above, the mean reactivity was 0.00, and thus the topical skin preparation comprising the nanocomposite in which vegan exosomes and niosomes are fused according to the present disclosure was determined to be a non-irritating substance and a safe substance for human skin, similar to the topical skin preparation of the control group.
[0194] Example 9: preparation of a hybrid nanocomposite in which plant-derived vegan exosomes and niosomes are fused
[0195] 9-1. Isolation and concentration of plant-derived vegan exosomes
[0196] Water was added to Centella asiatica leaves at a 10-fold weight ratio, and the mixture was finely ground using a mixer to induce primary cleavage. Homogenization was then carried out at 7000 rpm for 30 minutes to induce secondary cleavage, which ruptured the cell walls. After removing further impurities by centrifugation and using a 0.22 µm filter, the supernatant was subjected to a 100 kDa size reduction (MWCO) (PES membrane, Merck) using a tangential flow filtration (TFF) apparatus to purify and concentrate high-purity exosomes. Following confirmation of exosome sizes by dynamic light scattering, the average exosome size was approximately 177.7 nm.
[0197] 9-2. Preparation of vegan exosomes in which multiple substances bioactives are inserted
[0198] Plant-derived vegan exosomes into which multiple bioactive substances including PDRN, camellia oil and a peptide are inserted were prepared in the same manner as in Example 3.
[0199] 9-3. Preparation of a hybrid nanocomposite in which vegan exosomes plant derivatives and niosomes are fused
[0200] In the same way as in Example 5, plant-derived vegan exosomes into which the multiple bioactive substances are inserted, prepared in Example 9-2, were added to the niosomes prepared in Example 4 at a particle number of 1:1, and then subjected to an ultrasonic membrane fusion reaction (Sonies vibracell, 40 kHz, 10 min) in order to prepare a hybrid nanocomposite in which the plant-derived vegan exosomes and the niosomes are fused.
[0201] Example 10: preparation of a hybrid nanocomposite in which vegan exosomes derived from plant callus and niosomes are fused
[0202] 10-1. Callus culture
[0203] Camellia petals cut to an appropriate size were sterilized by immersing the petals in 10% (v / v) hydrogen peroxide for 10 minutes and in 70% (v / v) ethanol for 1 minute, then agitating the petals in a 2% (v / v) sodium hypochlorite solution for 30 minutes. A callus was grown by washing the sterilized camellia tissue with sterile water five or more times, then cutting it finely into pieces approximately 1 cm long, and then inoculating it onto Murashinge and Skoog medium (MS, 1962) containing sucrose, Gelrite, and growth regulators (indole-3-acetic acid, IAA; zeatin), before culturing it at 25°C for 8 weeks. The cultured callus was subcultured at new at 5 week intervals to proliferate and acclimatize it, and the stable proliferating callus was finally obtained after a new culture in suspension in an air-lift bioreactor under dark conditions at 25°C for 6 weeks.
[0204] 10-2. Isolation and concentration of vegan exosomes derived from plant callus
[0205] The callus culture solution prepared in Example 10-1 was homogenized using a high-pressure homogenizer (Scientz-150, Ningbo Scientz Biotechnology Co., Ltd). More specifically, the callus culture solution was homogenized by repeating a homogenization process one to three times in a microfluidizer (MF) at a pressure of 2000 bar for 20 minutes and then allowing it to stand at room temperature for 10 minutes. After homogenization using the microfluidizer, the efficiency in each homogenization condition was confirmed by further performing a homogenization process for 10 minutes (30 sec puise on, 30 sec puise off, 10 cycles) under a 20% power condition using a 500 W, 20 kHz ultrasonicator (VC505, Sonies & Materials, Inc.).
[0206] The homogenized callus was centrifuged at 1000xg for 30 minutes at room temperature and a supernatant was collected to remove mainly solids, and the collected supernatant was filtered through a 0.22 µm sterilizing filter to obtain an exosome solution.
[0207] The exosome solution obtained by filtration was subjected to exosome isolation and concentration using a tangential flow filtration (TFF) apparatus. The exosome concentration using the TFF was carried out with a 100 kDa molecular weight reduction (MWCO) filter (Pellicon® 2 Mini Ultrafiltration Module Biomax, Millipore) and concentrated to 1 / 10 of the total volume of the exosome solution.
[0208] 10-3. Preparation of vegan exosomes in which multiple substances bioactives are inserted
[0209] Vegan exosomes derived from plant callus into which multiple bioactive substances including PDRN, camellia oil and a peptide are inserted were prepared in the same manner as in Example 3.
[0210] 10-4. Preparation of a hybrid nanocomposite in which vegan exosomes plant callus derivatives and niosomes are fused
[0211] In the same way as in Example 5, the vegan exosomes derived from plant callus into which the multiple bioactive substances are inserted, prepared in Example 10-3, were added to the niosomes prepared in Example 4 at a particle number of 1:1, and then subjected to an ultrasonic membrane fusion reaction (Sonies vibracell, 40 kHz, 10 min) in order to prepare a nanocomposite hybrid in which vegan exosomes derived from plant callus and niosomes are fused.
[0212] Example 11: confirmation of a bioactive substance inserted into a hybrid nanocomposite in which vegan exosomes and niosomes are fused
[0213] It was confirmed whether the PDRN, which is a bioactive substance, had been correctly inserted into the hybrid nanocomposite in which vegan exosomes and niosomes are fused, prepared in example 5. To this end, the hybrid nanocomposite in which vegan exosomes and niosomes are fused from example preparation 5 was treated with deoxyribonuclease (DNase) and ribonuclease (RNase) in order to remove the uninserted PDRN and nucleic acids. More specifically, the hybrid nanocomposite in which vegan exosomes and niosomes are fused was treated with 0.1 mg / mL of DNase and 50 pg / mL of RNase, then reacted at 37°C for 30 minutes to hydrolyze and remove the PDRN not inserted into the exosomes, the PDRN was confirmed by electrophoresis, and a result of this is illustrated in [Fig.4].In electrophoresis, channel A was loaded with PDRN prior to insertion into the hybrid complex, and channel D was loaded with PDRN treated with DNase and RNase. In the preparation process, the hybrid complex in which vegan exosomes and niosomes are fused was loaded into channel B, and the hybrid complex from which the PDRN not inserted into the hybrid complex was removed by treatment with DNase and RNase was loaded into channel C.
[0214] Following electrophoresis, a PDRN band was identified in pathway A, and it was confirmed that the PDRN had been degraded by RNase and DNase in pathway D. In pathway B, both PDRN inserted into the hybrid complex and uninserted PDRN in a free state were observed. In pathway C, PDRN in a free state was removed by treatment with RNase and DNase, and only PDRN inserted into the hybrid complex was observed. This confirmed that the PDRN had been successfully inserted into the hybrid complex and that the complex had been correctly formed.
[0215] Example 12: Fluorescence microscopy measurement of a hybrid nanocomposite in which vegan exosomes and niosomes are fused
[0216] It was confirmed whether the hybrid nanocomposite in which vegan exosomes and niosomes are fused, prepared in Example 5, had been correctly prepared. To this end, a lipid bilayer of the vegan exosomes from Example 3 was stained using Dil dye (Ex / Em-553 / 570), which is red fluorescence, and a lipid bilayer of the niosomes from Example 4 was stained using DiO (Ex / Em-484 / 501), which is green fluorescence. Each of the exosomes Vegan and fluorescently stained niosomes were used to prepare a hybrid nanocomposite using the same procedure as in Example 5. Images of the prepared hybrid nanocomposite, in which vegan exosomes and niosomes are fused, were taken at respective fluorescence wavelengths using a confocal microscope, and the fluorescence images were fused to determine the hybridization of the vegan exosomes and niosomes. A result of this is illustrated in [Fig. 5].
[0217] As illustrated in [Fig. 5], it was confirmed that the red fluorescence of vegan exosomes and the green fluorescence of niosomes were both analyzed in the hybrid nanocomposite, and, when these two types of fluorescence were fused, a yellow fluorescence in which red and green are combined in the same structure was analyzed. Consequently, it was confirmed that the hybrid nanocomposite in which vegan exosomes and niosomes are fused, prepared using Example 5, had been prepared.
[0218] A composition comprising the hybrid complex comprising the multiple bioactive substances of this disclosure, wherein the hybrid complex is a hybrid complex in which vegan exosomes and niosomes are fused, may be prepared by the following formulation examples, but not limited to them.
[0219] Formulation example 1: cosmetic formulation
[0220] Example of formulation 1-1: softening lotion
[0221] A softening lotion comprising, as an active ingredient, a hybrid nanocomposite in which vegan exosomes and niosomes are fused according to the present disclosure was prepared by a conventional process as in Table 11 below.
[0222] [Tableauxll] Ingredient % by weight Hybrid nanocomposite in which vegan exosome proteins and niosomes are fused 5.0 Glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxyvinyl polymer 0.1 Ethanol 10.0 Triethanolamine 0.1 Preservatives, trace amounts of colorants, trace amounts of perfumes and trace amounts of purified water 77.8 Total 100.0
[0223] Example of formulation 1-2: nourishing lotion
[0224] A nourishing lotion comprising, as an active ingredient, a hybrid nanocomposite in which vegan exosomes and niosomes are fused according to the present disclosure was prepared according to a conventional process as in Table 12 below.
[0225] [Tables 12] Ingredient % by weight Hybrid nanocomposite in which vegan exosome proteins and niosomes are fused 5.0 Beeswax 4.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 Liquid paraffin 5.0 Squalane 5.0 Caprylic / capric triglyceride 5.0 Glycerin 3.0 Butylene glycol 3.0 Propylene glycol 3.0 Carboxyvinyl polymer 0.1 Triethanolamine 0.2 Preservatives, trace amounts of colorants, trace amounts of perfumes and trace amounts of purified water 64.7 Total 100.0
[0226] Example of formulation 1-3: nourishing cream
[0227] A nourishing cream comprising, as an active ingredient, a hybrid nanocomposite in which vegan exosomes and niosomes are fused according to the present disclosure was prepared according to a conventional process as in Table 13 below.
[0228] [Tables 13] Ingredient % by weight Hybrid nanocomposite in which vegan exosome proteins and niosomes are fused 5.0 Beeswax 10.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 Liquid paraffin 10.0 Squalane 5.0 Caprylic / capric triglyceride 5.0 Glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservatives, trace amounts of colorants, trace amounts of perfumes and trace amounts of purified water 51.8 Total 100.0
[0229] Example of formulation 1-4: massage cream
[0230] A massage cream comprising, as an active ingredient, a hybrid nanocomposite in which vegan exosomes and niosomes are fused according to the present disclosure was prepared according to a conventional process as in Table 14 below.
[0231] [Tables 14] Ingredient % by weight Hybrid nanocomposite in which vegan exosome proteins and niosomes are fused 5.0 Beeswax 10.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.8 Liquid paraffin 40.0 Squalane 5.0 Caprylic / capric triglyceride 4.0 Glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservatives, trace amounts of colorants, trace amounts of perfumes and trace amounts of purified water 22.5 Total 100.0
[0232] Example of formulation 1-5: buffer
[0233] A buffer comprising, as an active ingredient, a vegan exosome-based hybrid according to the present disclosure was prepared by a conventional process as in Table 15 below.
[0234] [Tables 15] Ingredient % by weight Hybrid nanocomposite in which vegan exosomes and niosomes are fused 5.0 Polyvinyl alcohol 13.0 Sodium carboxymethylcellulose 0.2 Allantoin 0.1 Ethanol 5.0 Nonylphenyl ether 0.3 Preservatives, trace amounts of colorants, trace amounts of perfumes and trace amounts of purified water 76.4 Total 100.0
[0235] Example of formulation 2: pharmaceutical formulation
[0236] Example of formulation 2-1: preparation of a gel
[0237] A gel was prepared by mixing a hybrid nanocomposite in which vegan exosomes and niosomes are fused according to the present disclosure with each ingredient in Table 16 below.
[0238] [Tableauxlô] Ingredient % by weight Hybrid nanocomposite in which vegan exosome and niosomes are fused 5.0 Butylene glycol 2.0 Glycerin 1.0 Disodium EDTA 0.02 Sodium benzoate 0.4 Caprylic glycol 0.2 Sodium lactate 0.5 Hydroxyethylcellulose 0.7 Purified water 90.18 Total content 100.0
[0239] Example of formulation 2-2: preparation of an ointment
[0240] An ointment was prepared by mixing a hybrid nanocomposite in which vegan exosomes and niosomes are fused according to the present disclosure with each ingredient in Table 17 below.
[0241] [Tables 17] Ingredient % by weight Hybrid nanocomposite in which vegan exosome proteins and niosomes are fused 5.0 Glyceryl monostearate 1.0 Sodium benzoate 0.4 Caprylyl glycol 0.2 Propylene glycol 12.0 Stearyl alcohol 20.0 White petrolatum 25.0 Purified water 36.4 Total content 100.0
[0242] Although specific portions of this disclosure have been described in detail above, it is apparent to those skilled in the art that such detailed descriptions are merely preferred embodiments, and that the scope of this disclosure is not limited by them. Accordingly, the substantial scope of this disclosure will be defined by the accompanying claims and their equivalents.
Claims
Demands
1. A process for preparing a hybrid nanocomposite in which vegan exosomes and niosomes are fused, the process comprising: (S 10) the preparation of vegan exosomes by isolating exosomes from plant-derived cells or microorganisms, excluding animal cells; (S20) the insertion of multiple bioactive substances into the vegan exosomes of step (S 10); (S30) the preparation of niosomes by mixing a nonionic surfactant, a stabilizer and a solvent, and carrying out high-pressure homogenization;and (S40) the fusion of vegan exosomes and niosomes by subjecting to ultrasonic treatment the vegan exosomes into which the multiple bioactive substances are inserted in step (S20) and the niosomes of step (S30), in which the hybrid nanocomposite forms a bilayer or a trilayer by irregularly arranging part of a bilayer which constitutes the vegan exosomes and part of a bilayer which constitutes the niosomes, and the multiple bioactive substances inserted into the vegan exosomes are positioned on or fixed to a surface of the hybrid nanocomposite, between the membranes of the hybrid nanocomposite, or inside the hybrid nanocomposite.;
2. A method according to claim 1, wherein the bioactive substance is one or more substances selected from the group consisting of proteins, peptides, extracellular matrices, nucleic acids, lipids, carbohydrates, drugs and phytochemicals.
3. A method according to claim 1, wherein the insertion at step (S20) is carried out by homogenizing a mixture of vegan exosomes and multiple bioactive substances at a pressure of 800 to 1200 bar using a homogenizer.
4. A method according to claim 1, wherein the high-pressure homogenization at step (S30) is carried out at 600 to 800 bar using a high-pressure homogenizer.
5. A method according to claim 1, wherein the niosomes of step (S30) are further mixed with an auxiliary emulsifier.
6. A process according to claim 1, wherein the mixture at step (S30) comprises 100 to 1000 parts by weight of the stabilizer and 180 to 220 parts by weight of the solvent, based on 100 parts by weight of the nonionic surfactant.
7. A method according to claim 1, wherein the vegan exosomes and niosomes of step (S40) are mixed with a particle number of 0.1 to 2:0.1 to 2 and subjected to ultrasonic treatment.
8. A method according to claim 1, wherein the ultrasonic treatment at step (S40) is carried out for 9 to 11 minutes using 30 to 50 kHz ultrasound.
9. Hybrid nanocomposite in which vegan exosomes and niosomes are fused and in which multiple bioactive substances are inserted, prepared by the preparation process according to any one of claims 1 to 8.
10. Hybrid nanocomposite according to claim 9, wherein the vegan exosomes are exosomes isolated from plant-derived cells, plant callus, plant stem cells, undifferentiated plant cells or microorganisms, excluding animal cells.
11. Hybrid nanocomposite according to claim 9, wherein the bioactive substance is one or more substances selected from the group consisting of proteins, peptides, extracellular matrices, nucleic acids, lipids, carbohydrates, drugs and phytochemicals.
12. Composition for delivering multiple bioactive substances comprising the hybrid nanocomposite in which vegan exosomes and niosomes are fused and in which the multiple bioactive substances are inserted, prepared by the preparation process according to any one of claims 1 to 8, wherein the hybrid nanocomposite has an average particle diameter of 100 to 200 nm, forms a bilayer or a trilayer by irregularly arranging a portion of a bilayer constituting the vegan exosomes and a portion of a bilayer constituting the niosomes, and the multiple bioactive substances inserted into the vegan exosomes are positioned on or attached to a surface of the hybrid nanocomposite, between the membranes of the hybrid nanocomposite, or within the hybrid nanocomposite, wherein the vegan exosomes are exosomes isolated from plant-derived cells or microorganisms, excluding animal cells, and the bioactive substance is one or more substances selected from the group consisting of proteins, peptides, extracellular matrices, nucleic acids, lipids, carbohydrates, drugs, and phytochemicals.
13. A cosmetic composition comprising, as an active ingredient, the hybrid nanocomposite in which vegan exosomes and niosomes are fused and in which the multiple bioactive substances are inserted, prepared by the preparation process according to any one of claims 1 to 8, wherein the hybrid nanocomposite has an average particle diameter of 100 to 200 nm, forms a bilayer or a trilayer by irregularly arranging a portion of a bilayer constituting the vegan exosomes and a portion of a bilayer constituting the niosomes, and the multiple bioactive substances inserted into the vegan exosomes are positioned on or attached to a surface of the hybrid nanocomposite, between the membranes of the hybrid nanocomposite, or within the hybrid nanocomposite, wherein the vegan exosomes are exosomes isolated from plant-derived cells or microorganisms,excluding animal cells, and the bioactive substance is one or more substances selected from the group consisting of proteins, peptides, extracellular matrices, nucleic acids, lipids, carbohydrates, drugs and phytochemicals.
14. Topical composition for cutaneous application, comprising, as an active ingredient, the hybrid nanocomposite in which vegan exosomes and niosomes are fused and in which the multiple bioactive substances are inserted, prepared by the preparation process according to any one of claims 1 to 8, in which the hybrid nanocomposite has an average particle diameter of 100 to 200 nm, forms a bilayer or a trilayer by irregularly arranging part of a bilayer that constitutes the vegan exosomes and part of a bilayer that constitutes the niosomes, and the multiple bioactive substances inserted into the vegan exosomes are positioned on or attached to a surface of the hybrid nanocomposite, between the membranes of the hybrid nanocomposite, or within the hybrid nanocomposite, in which the vegan exosomes are exosomes isolated from plant-derived cells or microorganisms, excluding animal cells, and The bioactive substance is one or more substances selected from the group consisting of proteins, peptides, extracellular matrices, nucleic acids, lipids, carbohydrates, drugs and phytochemicals.
